Ignite Creation Date:
2024-05-06 @ 8:02 PM
Last Modification Date:
2024-10-26 @ 3:18 PM
Study NCT ID:
NCT06221670
Status:
NOT_YET_RECRUITING
Last Update Posted:
2024-01-24
First Post:
2024-01-14
Brief Title:
Toripalimab Therapy After Resection in High-risk Stage IA2-IB NSCLC With no Driver Alterations EGFR or ALK
Sponsor:
Tianjin Medical University Cancer Institute and Hospital
Organization:
Tianjin Medical University Cancer Institute and Hospital
Conditions & Keywords Data
Conditions:
| Name |
|---|
| NSCLC |
Keywords: